Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 31, 2023
Distillery Therapeutics
Gut bacterial metabolite targeting NOX2 for abdominal aortic aneurysm
BioCentury | Jan 30, 2021
Distillery Therapeutics
Targeting CTSC to treat lung-metastatic breast cancer
DISEASE CATEGORY: Cancer
INDICATION: Breast cancer Inhibiting the lysosomal cysteine protease CTSC could suppress breast cancer lung metastases by blocking neutrophil extracellular trap (NET)
INDICATION: Breast cancer Inhibiting the lysosomal cysteine protease CTSC could suppress breast cancer lung metastases by blocking neutrophil extracellular trap (NET)
BioCentury | Jun 13, 2020
Translation in Brief
OSE identifies myeloid checkpoint target; plus a call from NCI for COVID-19 test proposals, Sinopharm vaccine data and more
BioCentury’s roundup of preclinical news
BioCentury | Jun 6, 2018
Translation in Brief
JAKs and clots
Brigham and Women’s team suggest JAK-2 inhibitors could treat thrombosis
Items per page:
1 - 10 of 18